Citrobacter amalonaticus Inhibits the Growth of Citrobacter rodentium in the Gut Lumen.


Journal

mBio
ISSN: 2150-7511
Titre abrégé: mBio
Pays: United States
ID NLM: 101519231

Informations de publication

Date de publication:
26 10 2021
Historique:
pubmed: 6 10 2021
medline: 8 2 2022
entrez: 5 10 2021
Statut: ppublish

Résumé

The gut microbiota plays a crucial role in susceptibility to enteric pathogens, including Citrobacter rodentium, a model extracellular mouse pathogen that colonizes the colonic mucosa. C. rodentium infection outcomes vary between mouse strains, with C57BL/6 and C3H/HeN mice clearing and succumbing to the infection, respectively. Kanamycin (Kan) treatment at the peak of C57BL/6 mouse infection with Kan-resistant C. rodentium resulted in relocalization of the pathogen from the colonic mucosa and cecum to solely the cecal luminal contents; cessation of the Kan treatment resulted in rapid clearance of the pathogen. We now show that in C3H/HeN mice, following Kan-induced displacement of C. rodentium to the cecum, the pathogen stably colonizes the cecal lumens of 65% of the mice in the absence of continued antibiotic treatment, a phenomenon that we term antibiotic-induced bacterial commensalization (AIBC). AIBC C. rodentium was well tolerated by the host, which showed few signs of inflammation; passaged AIBC C. rodentium robustly infected naive C3H/HeN mice, suggesting that the AIBC state is transient and did not select for genetically avirulent C. rodentium mutants. Following withdrawal of antibiotic treatment, 35% of C3H/HeN mice were able to prevent C. rodentium commensalization in the gut lumen. These mice presented a bloom of a commensal species, Citrobacter amalonaticus, which inhibited the growth of C. rodentium

Identifiants

pubmed: 34609899
doi: 10.1128/mBio.02410-21
pmc: PMC8510533
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0241021

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/R020671/1
Pays : United Kingdom

Auteurs

Caroline Mullineaux-Sanders (C)

Centre for Molecular Microbiology and Infection, Department of Life Sciences, Imperial College, London, United Kingdom.

Danielle Carson (D)

Centre for Molecular Microbiology and Infection, Department of Life Sciences, Imperial College, London, United Kingdom.

Eve G D Hopkins (EGD)

Centre for Molecular Microbiology and Infection, Department of Life Sciences, Imperial College, London, United Kingdom.

Izabela Glegola-Madejska (I)

Centre for Molecular Microbiology and Infection, Department of Life Sciences, Imperial College, London, United Kingdom.

Alejandra Escobar-Zepeda (A)

Microbiome Informatics Team, EMBL-EBI, Hinxton, United Kingdom.
Host-Microbiota Interactions Lab, Wellcome Trust Sanger Institute, Hinxton, United Kingdom.

Hilary P Browne (HP)

Host-Microbiota Interactions Lab, Wellcome Trust Sanger Institute, Hinxton, United Kingdom.

Trevor D Lawley (TD)

Host-Microbiota Interactions Lab, Wellcome Trust Sanger Institute, Hinxton, United Kingdom.

Gad Frankel (G)

Centre for Molecular Microbiology and Infection, Department of Life Sciences, Imperial College, London, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH